Inhibition of de novo Palmitate Synthesis by Fatty Acid Synthase Induces Apoptosis in Tumor Cells by Remodeling Cell Membranes, Inhibiting Signaling Pathways, and Reprogramming Gene Expression

[1]  D. Nomura,et al.  Diacylglycerol Metabolism and Signaling Is a Driving Force Underlying FASN Inhibitor Sensitivity in Cancer Cells. , 2015, ACS chemical biology.

[2]  B. Stiles,et al.  Short Term Feeding of a High Fat Diet Exerts an Additive Effect on Hepatocellular Damage and Steatosis in Liver-Specific PTEN Knockout Mice , 2014, PloS one.

[3]  I. Prior,et al.  Ras palmitoylation is necessary for N-Ras activation and signal propagation in growth factor signalling. , 2013, The Biochemical journal.

[4]  Li-jun Hou,et al.  Up-regulation of USP2a and FASN in gliomas correlates strongly with glioma grade , 2013, Journal of Clinical Neuroscience.

[5]  D. Colomer,et al.  Lipid raft-mediated Akt signaling as a therapeutic target in mantle cell lymphoma , 2013, Blood Cancer Journal.

[6]  John M. Asara,et al.  Glutamine supports pancreatic cancer growth through a Kras-regulated metabolic pathway , 2013, Nature.

[7]  Y. Henis,et al.  The role of palmitoylation in regulating Ras localization and function. , 2013, Biochemical Society transactions.

[8]  M. Sivaraja,et al.  Imidazopyridine-Based Fatty Acid Synthase Inhibitors That Show Anti-HCV Activity and in Vivo Target Modulation. , 2013, ACS medicinal chemistry letters.

[9]  Ajay Kumar,et al.  Fatty acid synthase inhibitor orlistat induces apoptosis in T cell lymphoma: role of cell survival regulatory molecules. , 2012, Biochimica et biophysica acta.

[10]  Hans Clevers,et al.  Wnt/β-Catenin Signaling and Disease , 2012, Cell.

[11]  Gerald C. Chu,et al.  Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism , 2012, Cell.

[12]  P. Ward,et al.  Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. , 2012, Cancer cell.

[13]  W. Mustain,et al.  Inhibition of fatty acid synthase attenuates CD44-associated signaling and reduces metastasis in colorectal cancer. , 2012, Cancer research.

[14]  Baiqu Huang,et al.  A Rac1/PAK1 cascade controls β-catenin activation in colon cancer cells , 2012, Oncogene.

[15]  Hong Wu,et al.  Integrative Survival-Based Molecular Profiling of Human Pancreatic Cancer , 2012, Clinical Cancer Research.

[16]  M. Calvani,et al.  Serum Levels of Fatty Acid Synthase in Colorectal Cancer Patients Are Associated with Tumor Stage , 2012, Journal of Gastrointestinal Cancer.

[17]  H. Aguilar,et al.  A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines , 2011, Breast Cancer Research.

[18]  Heidrun Karlic,et al.  Blockade of Fatty Acid Synthase Induces Ubiquitination and Degradation of Phosphoinositide-3-Kinase Signaling Proteins in Ovarian Cancer , 2011, Molecular Cancer Research.

[19]  Kai Simons,et al.  Membrane organization and lipid rafts. , 2011, Cold Spring Harbor perspectives in biology.

[20]  H. Waldmann,et al.  Raft Protein Clustering Alters N-Ras Membrane Interactions and Activation Pattern , 2011, Molecular and Cellular Biology.

[21]  Jeng-Jong Hwang,et al.  Antitumor effect of orlistat, a fatty acid synthase inhibitor, is via activation of caspase-3 on human colorectal carcinoma-bearing animal. , 2011, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[22]  F. Hanisch,et al.  Lipid rafts: signaling and sorting platforms of cells and their roles in cancer , 2011, Expert review of proteomics.

[23]  P. Dennis,et al.  PTEN loss in the continuum of common cancers, rare syndromes and mouse models , 2011, Nature Reviews Cancer.

[24]  D. Bar-Sagi,et al.  Regulating the regulator: post-translational modification of RAS , 2011, Nature Reviews Molecular Cell Biology.

[25]  M. Nowak,et al.  Distant Metastasis Occurs Late during the Genetic Evolution of Pancreatic Cancer , 2010, Nature.

[26]  M. Loda,et al.  Fatty acid synthase polymorphisms, tumor expression, body mass index, prostate cancer risk, and survival. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Jian-Ting Zhang,et al.  Biochemistry, molecular biology, and pharmacology of fatty acid synthase, an emerging therapeutic target and diagnosis/prognosis marker. , 2010, International journal of biochemistry and molecular biology.

[28]  Yuan Tian,et al.  Expression of Fatty Acid Synthase Depends on NAC1 and Is Associated with Recurrent Ovarian Serous Carcinomas , 2010, Journal of oncology.

[29]  M. Loda,et al.  Fatty acid synthase as a potential therapeutic target in cancer. , 2010, Future oncology.

[30]  Kai Simons,et al.  Lipid Rafts As a Membrane-Organizing Principle , 2010, Science.

[31]  H. Aguilar,et al.  Novel Inhibitors of Fatty Acid Synthase with Anticancer Activity , 2009, Clinical Cancer Research.

[32]  R. Shaw,et al.  The LKB1–AMPK pathway: metabolism and growth control in tumour suppression , 2009, Nature Reviews Cancer.

[33]  W. Berger,et al.  Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells. , 2009, Biochemical and biophysical research communications.

[34]  T. Osborne,et al.  Proto-oncogene FBI-1 (Pokemon) and SREBP-1 Synergistically Activate Transcription of Fatty-acid Synthase Gene (FASN)* , 2008, Journal of Biological Chemistry.

[35]  M. Loda,et al.  Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of β-catenin in prostate cancer , 2008, Laboratory Investigation.

[36]  M. Lisanti,et al.  Co-expression of fatty acid synthase and caveolin-1 in pancreatic ductal adenocarcinoma: Implications for tumor progression and clinical outcome , 2008, Cell cycle.

[37]  G. Parmigiani,et al.  Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.

[38]  Hai-Tao He,et al.  Raft nanodomains contribute to Akt/PKB plasma membrane recruitment and activation. , 2008, Nature chemical biology.

[39]  Teresa Puig,et al.  Fatty acid metabolism in breast cancer cells: differential inhibitory effects of epigallocatechin gallate (EGCG) and C75 , 2008, Breast Cancer Research and Treatment.

[40]  J. Menéndez,et al.  Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis , 2007, Nature Reviews Cancer.

[41]  Javier A Menendez,et al.  Targeting fatty acid synthase in breast and endometrial cancer: An alternative to selective estrogen receptor modulators? , 2006, Endocrinology.

[42]  Paolo Visca,et al.  Tissue microarray analysis of FAS, Bcl-2, Bcl-x, ER, PgR, Hsp60, p53 and Her2-neu in breast carcinoma. , 2006, Anticancer research.

[43]  R. Dhir,et al.  Fatty acid synthase gene overexpression and copy number gain in prostate adenocarcinoma. , 2006, Human pathology.

[44]  N. Ban,et al.  Architecture of mammalian fatty acid synthase , 2006 .

[45]  Timm Maier,et al.  Architecture of Mammalian Fatty Acid Synthase at 4.5 Å Resolution , 2006, Science.

[46]  T. Roskams,et al.  High‐level expression of fatty acid synthase in human prostate cancer tissues is linked to activation and nuclear localization of Akt/PKB , 2005, Journal of Pathology.

[47]  A. Abulrob,et al.  Interactions of EGFR and caveolin-1 in human glioblastoma cells: evidence that tyrosine phosphorylation regulates EGFR association with caveolae , 2004, Oncogene.

[48]  Jeffrey W. Smith,et al.  Orlistat Is a Novel Inhibitor of Fatty Acid Synthase with Antitumor Activity , 2004, Cancer Research.

[49]  S. Chirala,et al.  Fatty acid synthesis is essential in embryonic development: Fatty acid synthase null mutants and most of the heterozygotes die in utero , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[50]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[51]  P. W. Janes,et al.  Aggregation of Lipid Rafts Accompanies Signaling via the T Cell Antigen Receptor , 1999, The Journal of cell biology.